3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
cabozantinib
4
Nivolumab
2
Ipilimumab
2
zimberelimab
1
temsirolimus
1
salicylhydroxamic acid
1
orellanine
1
atezolizumab
1
Surveys and Questionnaires
1
Ropivacaine
1
Pluvicto
1
Methods
1
Health Promotion
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Genetic Counseling
1
Erlotinib Hydrochloride
1
Educational Status
1
Early Intervention, Educational
1
Docetaxel
1
Dacarbazine
1
Counseling
1
Blood Component Removal
1
Axitinib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled